Advertisement
Canada markets open in 8 hours 45 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7306
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    82.93
    +0.12 (+0.14%)
     

  • Bitcoin CAD

    88,011.12
    -3,394.31 (-3.71%)
     

  • CMC Crypto 200

    1,386.92
    -37.18 (-2.61%)
     

  • GOLD FUTURES

    2,325.30
    -13.10 (-0.56%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,460.00
    -204.50 (-1.16%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,702.49
    -757.59 (-1.97%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Apellis (APLS) Expands Deal for Targeted Complement Therapies

Zacks Equity Research
·3 min read

Apellis Pharmaceuticals, Inc. APLS announced that it has expanded its existing research and development (R&D) collaboration agreement with France-based privately held company, Affilogic, to develop and deliver targeted complement therapies into the brain.

Affilogic specializes in the discovery, development and combinations of affinity proteins named Nanofitins.

The companies expanded their deal to include the development of Nanofitins targeting the transferrin receptor (TfR), which helps carry drugs across the blood-brain barrier and the central nervous system.

Apellis entered into a collaboration agreement with Affilogic in 2018.

ADVERTISEMENT

Per the expanded agreement, Apellis will have exclusive, worldwide patent rights for all development projects, while Affilogic will be entitled to receive development milestone payments as well as royalties on net sales if a product is commercialized from the collaboration.

The latest deal looks a good fit for Apellis as it extends the company’s efforts to develop brain-active C3 inhibitors and deliver targeted complement therapies into the brain.

Apellis plans to file an investigational new drug (“IND”) application for APL-1030, a potential first-in-class brain-active C3 inhibitor, for treating neurodegenerative and other complement-driven diseases. The company also expects to file an IND application for ophthalmological candidate, APL-2006, to treat both wet age-related macular degeneration and geographic atrophy. The INDs are expected to be filed over the next 12 months.

Shares of Apellis have lost 6.9% so far this year compared with the industry’s decline of 26.3%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Earlier this month, Apellis submitted a new drug application (“NDA”) to the FDA seeking approval of pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration. The regulatory body’s decision on the NDA filing acceptance is expected in August 2022.

In May 2021, the FDA approved pegcetacoplan (marketed as Empaveli) as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria (“PNH”).

Empaveli is approved for treatment-naïve patients and for those switching from Alexion’s (now part of AstraZeneca) C5 inhibitor therapies for PNH, namely, Soliris and Ultomiris.

Last December, the European Commission approved Aspaveli to treat adult patients with PNH who are anemic after treatment with a C5 inhibitor for at least three months. The drug is marketed under the trade name Empaveli in the United States.

Several label studies on pegcetacoplan are currently underway. A potential approval of pegcetacoplan for additional indications will boost sales and drive growth for the company.

Zacks Rank & Stocks to Consider

Apellis currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. LPTX, Aeglea BioTherapeutics, Inc. AGLE and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.

Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.

Aeglea BioTherapeutics’ loss per share estimates narrowed has 19.4% for 2022 and 37.5% for 2023 in the past 60 days.

Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.

Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.

Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research